{
    "organizations": [],
    "uuid": "154c23209cd3a7f72c29f5f7179021c4478f3c5b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-helix-biopharma-signs-agreement-wi/brief-helix-biopharma-signs-agreement-with-promab-biotechnologies-to-co-developcar-t-for-hematological-malignancies-idUSFWN1R30AU",
    "ord_in_thread": 0,
    "title": "BRIEF-Helix Biopharma Signs Agreement With Promab Biotechnologies To Co-Develop Car-T For Hematological Malignancies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 21, 2018 / 12:21 PM / in 9 minutes BRIEF-Helix Biopharma Signs Agreement With Promab Biotechnologies To Co-Develop Car-T For Hematological Malignancies Reuters Staff 1 Min Read March 21 (Reuters) - Helix Biopharma Corp: * HELIX BIOPHARMA CORP. SIGNS COLLABORATION AGREEMENT WITH PROMAB BIOTECHNOLOGIES TO CO-DEVELOP CAR-T FOR HEMATOLOGICAL MALIGNANCIES Source text for Eikon: Further company coverage:",
    "published": "2018-03-21T14:18:00.000+02:00",
    "crawled": "2018-03-21T14:37:01.048+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "minute",
        "biopharma",
        "sign",
        "agreement",
        "promab",
        "biotechnology",
        "hematological",
        "malignancy",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "helix",
        "biopharma",
        "corp",
        "helix",
        "biopharma",
        "sign",
        "collaboration",
        "agreement",
        "promab",
        "biotechnology",
        "hematological",
        "malignancy",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}